Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > FOXO4-DRI for Sale > FOX04-DRI Hot Sale Wholesale Price 99% High Purity Sema/Reta Retatrutide Cagrilintide Nad+ Mt-II Peptides
FOX04-DRI Hot Sale Wholesale Price 99% High Purity Sema/Reta Retatrutide Cagrilintide Nad+ Mt-II Peptides buy - large image1
FOX04-DRI Hot Sale Wholesale Price 99% High Purity Sema/Reta Retatrutide Cagrilintide Nad+ Mt-II Peptides buy - image1
FOX04-DRI Hot Sale Wholesale Price 99% High Purity Sema/Reta Retatrutide Cagrilintide Nad+ Mt-II Peptides buy - image2
FOX04-DRI Hot Sale Wholesale Price 99% High Purity Sema/Reta Retatrutide Cagrilintide Nad+ Mt-II Peptides buy - image3
FOX04-DRI Hot Sale Wholesale Price 99% High Purity Sema/Reta Retatrutide Cagrilintide Nad+ Mt-II Peptides buy - image4
FOX04-DRI Hot Sale Wholesale Price 99% High Purity Sema/Reta Retatrutide Cagrilintide Nad+ Mt-II Peptides buy - image5
FOX04-DRI Hot Sale Wholesale Price 99% High Purity Sema/Reta Retatrutide Cagrilintide Nad+ Mt-II Peptides buy - image6

FOX04-DRI Hot Sale Wholesale Price 99% High Purity Sema/Reta Retatrutide Cagrilintide Nad+ Mt-II Peptides

28 Inquiries

Unit Price:

$64-75/MT FOB

Get Latest Price
CAS No.:

2460055-10-9

Grade:

Pharmaceutical Grade

Content:

99%

Port:

gz

Packaging:

10mg/vial 10vials/box

Price valid (until):

2026-10-15

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Retatrutide,Tirzepatide,GHK-Cu,TB500,Nad+

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


    Description  


    Sales manager:Nora
    whatsapp:+12817797656
    Email:lisa@qtsbio.com


    Product Name Retatrutide
    Appearance White powder
    CAS No. 2381089-83-2
    Application Weight Loss


       Product Function


    Retatrutide is an investigational weight-management medication being developed by Eli Lilly, a leading pharmaceutical company recognized for its advances in diabetes and obesity treatment. As a novel incretin-based therapy targeting metabolic pathways, retatrutide has demonstrated substantial effects on body weight reduction and metabolic health in clinical studies, making it a promising candidate for the treatment of obesity and related chronic conditions.

    Beyond its potential applications in obesity and metabolic disorders, preclinical research has explored several possible effects of retatrutide and related incretin-based therapies on neurological and psychological conditions. However, these potential applications remain investigational and require further clinical validation.

    Potential effects on depression and anxiety:
    Preclinical studies have suggested that incretin-based therapies may exhibit antidepressant- and anxiolytic-like effects. These findings indicate the possibility that such therapies may have future applications in the management of depression and anxiety disorders, although their efficacy and safety for these conditions have not yet been established in humans.

    Potential neuroprotective effects:
    Research has investigated whether incretin-based therapies may provide neuroprotective benefits that could be relevant to neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. Further studies are needed to determine whether these findings can translate into meaningful clinical outcomes.

    Potential effects on cognitive function:
    Animal studies have reported improvements in certain aspects of learning and memory following treatment with incretin-related therapies. These findings suggest a potential role in supporting cognitive health, although evidence from well-controlled human clinical trials remains limited.

    Potential applications in chronic pain:
    Preclinical research has explored the possible analgesic and anti-inflammatory properties associated with incretin-based therapies. While these findings are of scientific interest, retatrutide is not currently an established treatment for chronic pain, and its potential therapeutic role in this area requires further investigation.


    Product Application


    1. Retatrutide has attracted significant attention in the pharmaceutical field, particularly in research related to weight management and metabolic disorders.

      Retatrutide is a synthetic peptide-based therapeutic compound.

      Retatrutide acetate functions as a multi-receptor agonist targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

      Through activation of glucagon receptors and modulation of related metabolic pathways, retatrutide acetate promotes increased energy expenditure and contributes to significant reductions in body weight.

      Retatrutide acetate can be utilized as a research tool in studies investigating obesity and related metabolic conditions.

    FAQ

    1. How to make an order?
    Send me message and let me know what you need with quantity , then i will calculate to you

    2. What's the lead time and shipping ways?
    We will delivery to the package by UPS, FEDEX, DHL paket and YANWEN express to you after receive your payment, it would take around 5-15 days to your address.

    3. How do i keep the peptides when i receive it ?
    Peptides in the form of lyophilized powder can be transported at room temperature by vacuum packaging, while polypeptides in the dissolved state need to be refrigerated at 2°C - 8°C. For long-term storage, peptides should be stored in the form of lyophilized powder store at -20°C or -80°C in a sealed container with desiccant, which can avoid the degradation of peptides to the greatest extent.

    4. What's the payment methods?
    We could accept pay through Wise, Bank Transfer, Alipay USDT and BTC.


    ECHEMI Editorial Reference
    FOXO4-DRI (Retro-Inverso) is a synthetic, slightly modified version of the standard FOXO4 protein. The modification prolongs half-life of the protein and allows it to interfere with normal FOXO4 function. FOXO4-DRI has been shown in research to prevent normal FOXO4 binding to p53, thereby allowing for elimination of senescent cells, improved organ function, and younger tissue “biological age.” FOXO4-DRI impacts insulin signaling, cell cycle regulation, and oxidative stress signaling pathways. FOXO4-DRI is a cell penetrating peptide shown to selectively induce apoptosis of senescent cells thereby reversing effects of aging in animal studies.

    Basic Info
    Product Name:

    FOXO4-DRI

    Other Name:

    FOXO4-DRI;FOXO4 /FOXO4-DRI;FOX04-DRI (D-Retro-Inverso);Fox4-dri

    CAS No.:

    2460055-10-9

    Molecular Weight:

    0

    Color/Form:

    White to off-white

    Research
    Class:

    Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)

    Status:

    Investigational — Phase 3 (REDEFINE program, CagriSema combination)

    Mechanism:

    A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.

    Activity note:

    Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.

    Source:

    MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.

    Clinical Development:

    NCT05249895; NCT05249882

    References
    PubChem:

    PubChem

    Disclaimer:

    Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Retatrutide,Tirzepatide,GHK-Cu,TB500,Nad+

    Location:

    Beijing

    Year of Establishment:

    2026

  • Inquiry History
    28 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    FOXO4-DRI

    1 G Dec 3, 2023
    Germany

    foxo4-dri

    1 G Aug 23, 2026
    United States

    Fox04-dri

    1 G May 20, 2026
    United States

    hot-sale-high-purity-raw-powder-fox04-dri-nad-ghk-cu-mot

    2 PCS Dec 19, 2025
    United States

    foxo4 dri

    10 MT Dec 13, 2025
    United States

    Fox04

    10 MG Oct 30, 2024
    Norway

    FOXO4-DRI

    200 MG Sep 3, 2026
    United Kingdom

    High purity foxo4

    1 G May 31, 2026
    United Kingdom

    Foxo4-Dri

    10 MG May 5, 2026
    United States

    Fox04-dri

    100 MG Apr 28, 2026
    Cyprus

    Foxo4 dri

    10 MT Apr 4, 2026
    Cyprus

    FOXO4-DRI

    1 KG Feb 2, 2026
    United States

    FOX04-DRI

    10 PCS Jan 12, 2026
    United States

    FOX04

    10 PCS Jan 12, 2026
    United States

    Foxo4 Dri

    40 MG Sep 15, 2025
    United States

    Fox04 dri

    10 MT Jun 21, 2026
    United States

    FOX04-DRI powder

    10 MT May 29, 2026
    United States

    fox04

    1 G Apr 29, 2026
    United States

    FOXO4-DRI

    1 KG Mar 23, 2026
    United States

    Foxo4-Dri

    2  Nov 24, 2025
    • 1
    • 2
    • Go to Page Go
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.